Literature DB >> 6846938

Pulmonary disposition of tobramycin.

A C Braude, A Hornstein, M Klein, S Vas, A S Rebuck.   

Abstract

Each antibiotic has a characteristic penetration into respiratory secretions, influenced by serum concentration, protein binding, transport systems, and the presence of infection. Whereas previous studies have used only bronchial secretions and blood, in the present study, blood, bronchial secretions, and bronchoalveolar lavage (BAL) fluid were analyzed for tobramycin levels. In 10 studies in 9 patients, serum levels were significantly related to BAL fluid levels (r = 0.8, p less than 0.01) when both were expressed as a function of creatinine (mean BAL level +/- SD = 144 +/- 124 micrograms/mg creatinine; serum level, 293 +/- 216 micrograms/mg creatinine). The level of drug penetration in BAL fluid, expressed by the slope of the relationship between blood and fluid, was 0.5. The penetration of tobramycin into bronchial secretions ranged from 0 to 1.4 micrograms/ml, the ratio of secretions to serum being 0.2 (r = 0.68; p less than 0.05). It is concluded that the disposition of tobramycin in bronchial secretions and BAL fluid differ. Thus, sampling both fluids offers a more suitable method to study antibiotic pharmacokinetics in bronchi and alveoli.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846938     DOI: 10.1164/arrd.1983.127.5.563

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 2.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

3.  Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.

Authors:  Y J Valcke; M T Rosseel; R A Pauwels; M G Bogaert; M E Van der Straeten
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 5.  Assessment of drug disposition in the lung.

Authors:  A S Rebuck; A C Braude
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

6.  Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.

Authors:  Ashwin S Dharmadhikari; Mohan Kabadi; Bob Gerety; Anthony J Hickey; P Bernard Fourie; Edward Nardell
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 7.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

8.  Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients.

Authors:  Emmanuel Boselli; Dominique Breilh; Sarah Djabarouti; Christian Guillaume; Thomas Rimmelé; Jean-Baptiste Gordien; Fabien Xuereb; Marie-Claude Saux; Bernard Allaouchiche
Journal:  Intensive Care Med       Date:  2007-05-25       Impact factor: 17.440

9.  Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.

Authors:  C Muller-Serieys; C Bancal; M C Dombret; P Soler; G Murciano; M Aubier; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.